drugset / Trial / NCT01472653

Treatment Selection According to Skin Reaction to Cetuximab

NCT01472653 ↗

Phase 2 Unknown 120 enrolled Institute of Oncology Ljubljana
NaSingle-groupOpen-labelTreatment

Summary

The therapy of patients with locally advanced head and neck cancer will be adjusted to the grade of skin rush as recorded after the first two cycles of Cetuximab and Cisplatin, i.e. either with radioimmunotherapy (radiotherapy and Cetuximab) or radiochemotherapy (radiotherapy and Cisplatin.

Timeline

Start
2011-12
Primary completion
2014-03
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 250 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 30 mg/m2 Intravenous